RUNX1 and acute promyelocytic leukemia: Of the 278 patients without myelodysplastic cytogenetic abnormalities, APL or core binding factor (CBF)‐AML who received molecular testing, testing for NPM1, CEBPA, and RUNX1 was reported in 80.9%, 60.1%, and 31.3% of patients, respectively.